Understanding the Massive Market Potential of Monoclonal AntibodiesDailyFinanceOver the past several years, monoclonal antibodies have revolutionized cancer treatments. Monoclonal antibodies are laboratory-produced molecules that mimic naturally produc…
Understanding the Massive Market Potential of Monoclonal AntibodiesMotley FoolOver the past several years, monoclonal antibodies have revolutionized cancer treatments. Monoclonal antibodies are laboratory-produced molecules that mimic naturally produce…
|
Powerful new option for treating vasculitis
News-Medical.net Among patients receiving rituximab, 64 percent were in remission at six months, 48 percent at one year and 39 percent at 18 months, compared to 53 percent, 39 percent and 33 percent for standard therapy. “The FDA approved rituximab for vasculitis based … UAB Part of Study of New Drug for VasculitisNewswise (press release) |
New method generates unlimited, high-quality antibodies for genetics researchHealthCanal.comModern genomic studies rely on precise and sophisticated technology, but the antibodies used to identify proteins that control gene expression can be unreliable…
UAB Part of Study of New Drug for VasculitisNewswise (press release)While standard therapy consists of daily oral doses of a cancer drug called cyclophosphamide, followed by azathioprine, an immunosuppressant often used in organ transplant, researchers…
UAB part of study of new drug for vasculitisUAB NewsWhile standard therapy consists of daily oral doses of a cancer drug called cyclophosphamide, followed by azathioprine, an immunosuppressant often used in organ transplant, researchers showed that fou…
Maintenance Rituximab in Advanced Follicular LymphomaCancer NetworkMaintenance therapy with rituximab(Drug information on rituximab) showed some improvement over observation, though it did not reach significance, among older patients with advanced foll…
|
BIOCAD Company and KOÇAK FARMA Sign a Definitive Agreement on Rituximab
Healthcare Global A Definitive Agreement on export of rituximab API produced by CJSC BIOCAD to Turkey was signed on August 13th, 2013 between CJSC BIOCAD and KOÇAK FARMA, a leading Turkish pharmaceutical company with strong presence in the area of oncology. |
|
安斯泰来在美推出他克莫司缓释胶囊（Astagraf XL）
生物谷 2013年8月24日讯/生物谷BIOON/ –安斯泰来（Astellas）8月23日宣布，在美国推出Astagraf XL（他克莫司缓释胶囊，tacrolimus extended release capsules），该药与霉酚酸酯（MMF）及皮质类醇联用、结合或无巴利昔单抗 … |
|
BIOCAD Company and KOÇAK FARMA Sign a Definitive Agreement on Rituximab
PR.com (press release) A Definitive Agreement on export of rituximab API produced by CJSC BIOCAD to Turkey was signed on August 13th, 2013 between CJSC BIOCAD and KOÇAK FARMA, a leading Turkish pharmaceutical company with strong presence in the area of oncology. |